Compositions for use to treat advanced glycation end products-dependent ocular diseases Universiteit Gent
The present invention relates to the treatment of blindness due to age-related presbyopia, age- related macular degeneration (AMD), diabetic retinopathy (DR) and/or diabetic macular edema (DME) in a human or animal. Age-related presbyopia is the loss of accommodation in any individual more than 40-50 years old, currently treated by reading glasses. AMD is the most common cause of irreversible loss of sight in persons >65 years in the western world. At the time being no treatment is available for the dry form of AMD. The dry form of AMD is characterized by vision threatening Drusen, which ...